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BIOSYNTHETIC PATHWAYS OF PRO-RESOLVING LIPID MEDIATORS IN 
VASCULAR CELLS 
SEVAN R. KOMSHIAN 
 
ABSTRACT 	  
Introduction: Specialized pro-resolving lipid mediators (SPM) such as resolvin-D1 
(RvD1) act to resolve vascular inflammation and may guard against the progression of 
restenosis following cardiovascular interventions. Stimulating synthesis of these 
mediators directly in vascular cells may increase their local availability, and thus, protect 
against restenotic injury. However, the ability of endothelial (EC) and vascular smooth 
muscle cells (VSMC) to produce SPMs from their polyunsaturated fatty acid precursor 
decosahexaenoic acid (DHA) via lipoxygenase (LO) enzymatic transformation remains 
unknown. We sought to determine whether vascular cells produce SPMs from DHA and, 
if they do, how inflammation and mechanical injury of the vasculature alter biosynthesis. 
  
Methods: Primary cultures of human saphenous vein endothelial and smooth muscle 
cells were treated with DHA in cell culture media (+ 10% serum) for 4h-24h. Freshly 
dissected rabbit aorta was incubated intact or following gentle endothelial denudation in 
cell culture media (+10% serum) with or without DHA for 48h. SPM levels in media 
were quantified by LC-MS/MS and ELISA and lipoxygenase expression and localization 
were assessed by western blotting and immunofluorescence staining, respectively.  
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Results: EC and SMC receiving media without DHA did not synthesize SPMs within the 
detection limits of the assay, whereas DHA treatment produced 17-HDHA, 14-HDHA, 
Mar1, RvD5, RvD2, and a dose and time-dependent increase in RvD1 production in EC 
(10.1 ±1.0 pg for 1000nM at 24h) and SMC (7.4 ± 0.2 pg for 1000nM at 24h). Intact 
rabbit aorta incubated in DHA+ media produced 0.24 ± 0.05 pg RvD1/mg tissue whereas 
aorta incubated in DHA− media produced 0.13 ± 0.007 pg RvD1/mg tissue. Moreover, 
EC-denuded aortas produced less RvD1/mg tissue than intact aortas. 5-LO was expressed 
in both cell types, however DHA induced 5-LO expression in EC (1.3 fold -DHA) but not 
in SMC. DHA promoted a nuclear to cytoplasmic shift of 5-LO in both EC and SMC. 
Finally, TNF-α stimulated an increase in RvD1 production in EC. 
 
Conclusions: Human vascular cells and rabbit vascular tissue can biosynthesize SPMs de 
novo from their precursor DHA, signifying a new source of SPMs in the vasculature. 
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INTRODUCTION 
 
Cardiovascular disease is the leading cause of mortality in the US, accounting for 
600,000 deaths per year, and is on the verge of becoming the most common medical 
concern worldwide.1,2 Cardiovascular risk factors such as hypertension, diabetes, smoking 
and advancing age contribute to the development of atherosclerotic plaques, which cause 
narrowing of the cardiac and systemic vasculature.3–5 This manifests clinically as angina 
pectoralis and myocardial infarctions in the coronary system, transient ischemic attacks 
and ischemic strokes in the cerebral vascular system, and claudication and loss of limb in 
the peripheral vascular system. Atherosclerosis is a chronic and progressive disease 
which often requires surgical or endovascular intervention.6  
Although these interventions are initially effective in reintroducing circulation to 
obstructed arteries, they cause inflammation within the vessel wall. Inflammation is 
initially necessary for healing post-intervention. However, in excess it causes 
pathological changes within the vessel.7 The end product of these changes is neointimal 
hyperplasia, which causes restenosis. Thus, the interventions aimed at treating obstructed 
arteries often themselves lead to obstruction of the blood vessel.   
Whereas we previously thought resolution of inflammation was a passive process, 
we now know that specialized lipid mediators play an active role in resolution.8 These 
appropriately named specialized pro-resolving lipid mediators (SPMs) are essential to 
avoiding neointimal hyperplasia and the associated clinical consequences of restenosis.  
There has recently been evidence that restenosis can be viewed as a “resolution deficit” 
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within the vessel wall.9 However, little is known about the biosynthetic pathways of 
SPMs in vascular cells.  This knowledge would be of great clinical significance, as it 
would open the door for new therapeutic strategies.   
We set out to establish SPM production in human endothelial cells (ECs) and 
vascular smooth muscle cells (VSMCs), investigate the molecular pathways through 
which SPMs are produced in these cells, assess production of SPMs after administration 
of a precursor lipid, and define the effect of inflammation on SPM biosynthesis. By 
achieving these aims, we hope to ultimately introduce the foundation for new approaches 
to avoiding restenosis after vascular intervention.    
 
Atherosclerosis Pathophysiology 
 Atherosclerosis is a chronic inflammatory disease of the vasculature characterized 
by lipid insudation and eventual fibrous accumulation in the intimal layer of large 
arteries.10,11 In the past atherosclerotic lesions, or atheromas, were thought to be 
composed solely of lipid stores, but it is now understood that chronic inflammation and 
the immune response play a critical role in atherogenesis.12 In fact, T cells, macrophages, 
and mast cells form major components of atheromas.13–15 Connective tissue elements, 
endothelial cells, smooth muscle cells, lipids, and debris constitute the remaining portion 
of the lesion.13 
The progression of atherosclerosis is a dynamic process dependent on the 
interplay of multiple inflammatory factors.  When LDL cholesterol accumulates in the 
arterial intima and is subsequently oxidized through free radical and enzymatic reactions, 
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there is a release of oxidized phospholipids.16 In conjunction with a pattern of 
hemodynamic flow, these phospholipids induce the overexpression of intercellular 
adhesion molecules (eg. VCAM-1) in endothelial cells.19 Overexpression of adhesion 
proteins produces a steep rise in intimal macrophage count due to the increased rate of 
diapedesis and maturation of entering monocytes. Once in the vessel, macrophages 
phagocytose oxidized LDL via their scavenger receptors. 17 Foam cells that are 
characteristic of atherosclerotic lesions are subsequently formed when enzymatic action 
fails to digest the internalized LDL as it accumulates in the cytosol.11  
As this process continues, a visible collection of intimal foam cells, called a fatty 
streak, forms. Although often asymptomatic and present universally in the general 
population after the first decade, fatty streaks precede atheroma formation.13 As foam 
cells accumulate beneath the endothelium, they initiate a cascade of specific cell 
reactions and release various cytokines, including Tumor necrosis factor alpha (TNF- ) 
and Interleukins such as (IL-1 ), that initiate lesion formation.18 These cytokines further 
induce the expression of chemotactic and endothelial cell adhesion molecules which 
recruit additional monocytes to the forming lesion.19 Thus, the initiation of atherogenesis 
produces a cyclical chain of events that furthers growth of the fatty streak. 
Atherosclerotic plaque formation caused by vascular smooth muscle cell 
proliferation and migration, fibrous accumulation, and calcification within the intima 
distinguishes atherosclerotic lesions from precursor fatty streaks. Various enzymatic 
products released from foam cells start a cascade of events, beginning with the activation 
of endothelial growth factor receptor by oxidative stressors.20,21 Epidermal growth factor 
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proceeds to activate specific matrix metalloproteinases (MMP), which cleave the cell to 
cell adhesion molecule N-cadherin in the extracellular matrix.22 This frees VSMCs to 
migrate freely from the media to the intima along the chemotactic gradient established by 
cytokines released from the same foam cells. Once in the intima, VSMC cell 
proliferation, fibrosis, and calcium deposition forms a solid plaque.23As the plaque 
increases in size, it extends into the arterial lumen and diminishes blood flow. 
Occasionally, atherosclerotic plaques may rupture, contributing to coronary 
thrombosis. Such an event occurs as a direct action of the cytokines, proteases, and free 
radicals produced from the activated foam cells and T cells.24 These molecules, 
particularly the MMPs, destabilize fibrous plaques through digestion of the collagenous 
extracellular matrix and the basement membrane of endothelial cells.25 Such degeneration 
of connective tissue support leaves the atheroma weak and increasingly susceptible to 
physical damage. Upon rupture, the plaque’s fibrous core, which contains tissue factor, 
becomes exposed to circulating coagulation proteins and initiates thrombus formation.10 
Formation of intraarterial thrombus may cause acute ischemia to end-organs, distally.26,27  
 
Atherosclerosis Treatment  
 Pharmacotherapy 
 Various noninvasive options exist that are aimed at blocking pro-inflammatory 
pathways responsible for the progression of the disease.  Management of risk factors such 
as hypertension and diabetes with lifestyle modification and medications remain crucial 
in the treatment for atherosclerotic disease. Statins and COX-2 inhibitors such as aspirin 
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are also commonly employed as pharmacologic agents.28,29 Other more specific agents 
that has shown promise against atherogenesis are TNF-alpha inhibitors and vaccination 
with oxidized LDL or specific heat shock proteins.30 However, similar to other agents, 
these novel approaches are considered preventative and unable to sufficiently limit 
atherosclerosis pathology following progression of atherogensis and thrombosis.  Despite 
maximal medical therapy, atherosclerosis remains a progressive disease.   
  
Interventional 
 In cases of severe or symptomatic stenosis, various interventional measures can 
be taken to alleviate atherosclerosis. These include endovascular techniques such as 
angioplasty and stent placement as well as surgical procedures such as endarterectomy 
and bypass grafting. With the increasing prevalence of athereosclerotic disease, such 
procedures produce a major strain on the healthcare system.  In the United States, costs 
associated with vascular intervention is in excess of $21 billion annually, with a large 
portion of this burden being from reintervention needed for restenosis.31,32  
The problem of restenosis is in large part due to inflammation caused by the 
procedures themselves. Both endovascular and open surgical interventions cause 
inflammation to the vessel wall via stretch of the vessel wall from angioplasty, foreign 
body reaction to intravascular stents or surgical manipulation of the vasculature. This 
inflammation is initially necessary for vascular healing. However, when persistent or in 
excess it causes vascular smooth muscle cell migration from the tunica media to the 
tunica intima followed by proliferation and secretion of extracellular matrix within the 
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intima. The end-product of this process is neointimal hyperplasia and associated 
restenosis.    
Initiated by biomechanical injury of the endothelium, this process begins when 
the subendothelium is exposed to blood flow.  This results in platelet adhesion and 
aggregation to the injured segement.33 Activated upon adhesion, platelets release 
cytokines, including TNF-α, IL-1β, and MCP-1, which recruit leukocytes to the source of 
vascular damage.7,34–36 These inflammatory cells produce cellular products that induce 
further recruitment of leukocytes and initiate the migration and proliferation of VSMCs 
and adventitial fibroblasts.37 Within a week to a month following endovascular or surgical 
intervention, normally inactive and contractile VSMCs become activated and migrate 
from the medial layer of the artery into the neointima.38 Proliferation of VSMCs and 
remodeling of the extracellular matrix in the vessel wall caused by MMP-9 further 
accelerates this process.39 Ultimately, the neointimal hyperplasia resulting from the 
accumulation of VSMCs and extracellular matrix along the intimal wall causes luminal 
narrowing. Due to diminished blood flow, restenosis limits the long-term benefits of 
vascular procedures. For example, angioplasty of the femoral artery results in patency 
rates below 40% after one year.40 Durability of stenting and bypass is only slightly 
higher.41–44  
 Drug eluting stents (DES), when inserted at the sight of intervention, have arisen 
as a possible tool for limiting vascular inflammation and protecting against neointimal 
hyperplasia and restenosis.45 Currently used DES agents, including paclitaxel and 
sirolimus, have been shown to inhibit VSMC proliferation and extracellular matrix 
	  7 
formation due to their antimitotic actions.46,47 However, the non-specific actions of these 
cytotoxic agents also inhibits reendothelialization by endothelial cells, a normally 
protective process after injury.  The chronically exposed subendothelium perpetuates 
chronic inflammation and adhesion of platelets and coagulation factors, which can lead to 
thrombosis and luminal narrowing at any time.48–51 Thus, DES insertion may not only fail 
to regulate vascular inflammation but cause additional damage. Because of these 
complications, no absolute pharmacotherapeutic options currently exist to improve the 
results of surgical revascularization procedures in the treatment of atherosclerosis. 
  
Lipid Mediators and the Resolution of Vascular Inflammation 
 Resolution of Acute Inflammation 
 Acute inflammation plays a central role in response to vascular injury and is 
necessary for tissue repair. However, the resolution of inflammation is just as critical as 
its initiation to prevent scarring, tissue damage, and predisposition for thrombosis that 
may result from persistence of leukocytes and the other cells they recruit. In the intima of 
the vasculature, resolution of inflammation is essential in limiting neointimal hyperplasia 
and stenosis. It is the failure of resolution that leads to the pathological progression of 
atherosclerosis and the low patency of interventional treatments.  
It is important to note that suppression of inflammation is not the same as 
resolution. Targeting the very early stages of the inflammatory response is not sufficient 
for preventing chronic inflammation in vessels already under pathologic distress. In such 
cases, leukocytes already present in the tissue persist in releasing cytokines involved in 
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recruitment of other leukocytes, migration of VSMCs, and fibrosis. Furthermore, 
developing neointimal hyperplasia cannot subside independently, even in the absence of 
an active inflammatory response. These inflammatory processes must be resolved to 
allow the restoration of the inflamed vessel to its normal status.  
 Though until recently considered a passive process, the discovery of specialized 
pro-resolving lipid mediators derived from polyunsaturated fatty acids (PUFA) has 
suggested that resolution of acute inflammation may instead be actively regulated.52–54 
The four classes of SPMs that mediate this process include the lipoxins (LXs), derived 
from ω-6 PUFA arachidonic acid (AA), and the resolvins (RvDs), protectins (PDs), and 
maresins (MaRs) derived from the ω-3 PUFAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA).55–57 These molecules were discovered through the 
biochemical analysis of exudates produced in self-limited models of sterile inflammation. 
In this model, an air filled cavity was produced under the skin that remained sterile until 
injection of proinflammatory stimuli that initiated acute inflammation. Inflammation was 
shown to spontaneously resolve, and analysis of the exudates using a lipidomic approach 
and liquid chromatography–tandem mass spectrometry (LC-MS/MS) revealed the 
presence of novel lipid mediators in the resolving exudate.53  
SPMs, have displayed anti-inflammatory and pro-resolving effects in a variety of 
animal models, including sepsis, peritonitis, colitis, retinopathy, and periodontal 
disease.58–62 Whereas many molecules exist that are capable of suppressing the 
inflammatory response, SPMs are unique in their ability to stimulate the resolution stage 
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involved in returning inflamed tissue to homeostasis. In this respect, SPMs are of 
particular interest for their pro-resolving affects in a vascular setting. 
 
Anti-inflammatory and Pro-resolving Actions of SPMs 
Before delving into the unique pro-resolving affects of RvDs and other SPMs in 
vascular injury, it is important to mention that the initiation of inflammation begins with 
the production of arachidonic acid derivatives. These pro-inflammatory lipid mediators 
include prostaglandins such as PGE2 and PGI2 involved in vasodilation and leukotrienes 
such as LTB4 involved in chemotaxis and adhesion of polymorphonuclear neutrophils.63,64 
In concert with other cytokines and complement proteins, these molecules set the stage 
for leukocyte migration into tissue.  
The anti-inflammatory affects of SPMs begin through attenuation of this initial 
leukocyte infiltration by their omega-3 fatty acid precursors. EPA and DHA compete 
with AA as substrates for the lipoxygenases involved in eicosanoid production, limiting 
production of prostaglandins and leukotrienes and promoting synthesis of SPMs in a 
process called “class-switching” (Figure 1).65 Furthermore, EPA and DHA embedded in 
the membranes of leukocytes significantly alter membrane phospholipid composition and 
limit fluidity, negatively altering leukocyte activation, proliferation, and cytokine 
release.66 Thus, these precursors act to block the inflammatory process in its early stages. 
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Once the inflammatory process progresses, SPMs prevent the infiltration of 
circulating leukocytes into the vessel wall. In endothelial cells, LXs and RvDs retard the 
permeability of vessels to neutrophils by down regulating cell adhesion molecules such as 
VCAM-1.67 Similarly, RvD1 reduces production of potent inflammatory cytokines such 
as MCP-1 and PDGF-B.68 Such affects prevent inflammatory cells from gaining access to 
and disrupting tissue composition and function. This might be especially important in the 
context of atherosclerosis, where limiting the recruitment of phlogistic monocytes 
prevents accumulation of foam cells and the resulting development of plaque.  
SPMs also act to clear leukocytes that have already infiltrated vascular tissue. 
This process begins by signaling for the elimination of granulocytes already at the site of 
 
Figure 1. Temporal progression of lipid mediator class switching. 
Following pathological insult, eicosanoids are essential in initiating the inflammatory 
response. Prostaglandins and leukotrienes signal for neutrophil passage into the tissue 
as part of the standard vascular response. The acute inflammatory response terminates 
with lipid mediator class switching, as LXs and RvDs recruit nonphlogistic 
monocytes, which clear apoptotic neutrophils through efferocytosis. Resolution 
returns inflamed tissue to homeostasis.119  
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injury through their phagocytosis by macrophages. SPMs stimulate the nonphlogistic 
recruitment of monocytes, which transform into macrophages programmed to clear 
apoptotic neutrophils.69,70 The clearance of leukocytes indirectly mediates further anti-
inflammatory and pro-resolving actions of the inflamed tissue. Uptake of apoptotic 
neutrophils causes macrophages to release TGF- 1, an anti-inflammatory cytokine that 
decreases signaling of toll-like receptors on leukocytes, reducing their activity.71   
Interestingly, at the site of inflammation, the process of neutrophil apoptosis is 
itself regulated and may be induced by RvDs and LXs which override the NF-κB and I -
B  inflammatory pathways.72 This also results in the inhibition of TNF, IL-1, IL-6, IL-8 
and IL-12 production in endothelial cells and monocytes.73 Thus, as SPMs initiate 
resolution by stimulating neutrophil apoptosis and their nonphlogistic clearance, they 
indirectly prevent further inflammatory infiltration of the inflamed tissue.74 
Such combined anti-inflammatory and pro-resolving affects of SPMs are also 
observed in combatting progression of neointimal hyperplasia. In attenuating 
proliferation, restricting migration, and preventing the phenotypic switch characterized 
by loss of contractile protein expression in VSMCs, RvD1 actively regulates intimal 
thickening and limits stenotic narrowing of the vasculature.9,75 In the case of plaque 
rupture, resolvins also restrict the inflammation driven accumulation of circulating 
platelets.76 This is in part accomplished through SPM regulated phagocytosis of apoptotic 
cells, which causes release of vascular endothelial growth factor, stimulating the 
reendothelialization of blood vessels and protection of intima from circulating leukocytes 
and coagulation factors.77As a result, SPMs appear to limit the progression of two of the 
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most devastating inflammatory features of vascular injury: neointimal hyperplasia and 
thrombosis following plaque rupture. Such actions are essential for restoring inflamed 
vessels to normal conditions. 
 
DHA Derived SPM Biosynthesis 
Given their beneficial affects in resolving vascular inflammation, SPM pathways 
have arisen as a potential therapeutic means of addressing cardiovascular disease.78 SPMs 
must be produced at adequate levels to effectively manage their pro-resolving roles at the 
site of inflammation.79 Thus, understanding how to increase production or availability of 
SPMs in a vascular setting is of clinical interest. In this context, it is necessary to 
understand the process of their biosynthesis. Here, we focus on the pathways of SPM 
production derived from DHA. 
As is the case for other biological mediators, SPM production from DHA requires 
substrate availability as well as proper expression, activity, and cellular localization of the 
enzymes involved. In humans, the basal serum concentration of unesterified DHA is 
roughly 2-4μM with an increase of up to 500% following ω-3 supplementation of 
1.5g/day over six weeks.80–82 Meanwhile, blood levels of RvD1 in healthy individuals are 
30.9pg/ml, and other DHA derived resolvins, protectins, and maresins have been 
measured at varying but comparable amounts.83 Conversion of DHA to these products via 
oxygenation by the lipoxygenases has been observed through liquid 
chromatography/tandem mass spectrometry-based informatics (Figure 2).54,74 The final 
products of these specific enzymatic reactions are stereoselective, with the S 
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stereoisomers formed through 15-lipoxygenase (15-LO) or 12-lipoxygenase (12-LO) 
activity and R stereoisomers triggered by aspirin acetylated COX-2.59,84 
 
Figure 2. SPM biosynthesis from DHA. 
A) DHA is converted into 17-hydroxy-DHA (17-HDHA) by 15-lipoxygenase, which 
undergoes further transformation into resolvins such as RvD1 by 5-lipoxygenase or into 
protectins such as PD1 by epoxidation hydrolysis. Meanwhile, 12-lipoxygenase converts 
DHA into 14-hydroxy-DHA (14-HDHA) and 5-lipoxygenase converts 14-HDHA into 
maresins such as MaR1.85 B) A detailed schematic of resolvin biosynthesis from DHA 
with a complete illustration of enzymatic oxidation steps, intermediates, and products.79 
A	  
B
A	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 15-LO and 12-LO oxidation of DHA to 17-hydroxy-DHA (17HDHA) and 14-
hydroxy-DHA (14HDHA) appears to be the rate-limiting step in the biosynthesis of 
RvDs, MaRs, and PDs.68 15-LO and 12-LO preferentially bind to lipid bilayers, and 
different isoforms have comparable activity that increase upon action by inflammatory 
cytokines.86–88 In macrophages, expression of each enzyme has also been shown to 
increase under inflammatory conditions in a time dependent manner.89–91 Amplifying 
production of SPMs through such increases in activity and expression of these enzymes 
has proven to protect against vascular injury.68 However, heightened expression of 15-LO 
and 12-LO can also be harmful.92 Because the substrate specificity of both 15-LO and 12-
LO are equivalent for AA, EPA, and DHA, increased activity and expression of these 
enzymes contributes to the increased biosynthesis of pro-inflammatory lipid 
mediators.93,94 Though both enzymes have been identified in ECs and VSMCs, little is 
known about how changes in their expression levels either protect from or contribute to 
vascular inflammation.95,96 Therefore, it would be of particular interest to track their 
expression accompanying SPM biosynthesis in vascular cells.  
Similarly, it is unclear how 5-lipoxygenase (5-LO) mediates a pro-resolving 
response in EC and SMC. Acting further downstream in the pathway of DHA derived 
SPM biosynthesis, 5-LO also catalyzes synthesis of both pro-inflammatory and pro-
resolving lipid mediators in vascular cells.79,97,98 Consequently, increased activity and 
expression of 5-LO from inflammatory signaling has both protective and destructive 
affects, as is the case for the other lipoxygenases.74,99–101 In fact, inhibition of 5-LO as a 
means to prevent leukotriene biosynthesis has arisen as a potential treatment for 
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inflammatory diseases, including atherosclerosis.102,103 However, because of its potential 
involvement in SPM production from DHA, alternatives to 5-LO inhibition are 
preferable.  
Here, the answer may lie in the enzyme’s cellular localization. Localization is 
determined by phosphorylation of various amino acids in 5-LO, where phosphorylation at 
Ser-271 promotes and and phosphorylation at Ser-523 suppress nuclear localization.99,104 
Ser-271 is phosphorylated by a member of the mitogen-activated protein kinase family 
p38-MAPK, which has been shown to be activated by AA.105 Meanwhile, 
phosphorylation of Ser-523 is mediated by protein kinase A (PKA), which is activated by 
a variety of signals, including RvD1 and LXA4.106–108 Unphosphorylated Ser-271 5-LO 
and Ser-523 phosphorylated 5-LO are inhibited from migrating into the nucleus across 
the perinuclear membrane, the site of leukotriene synthesis, and remain at a higher 
concentration in the cytosol where they can interact with COX-2 and the other 
lipoxygenases to produce SPMs.99,104,109 Thus, in regulating subcellular localization, 
phosphorylation affects the substrates and co-dependent enzymatic interactions available 
to 5-LO, potentially influencing the production of SPMs over that of leukotrienes.  
Despite the observed expression of 15-LO, 12-LO, and 5-LO in EC and VSMC, it 
remains unclear whether vascular cells are capable of producing SPMs. Studies in other 
cell types signify that the presence of this biosynthetic machinery is sufficient for SPM 
production. Enzymatic transformation to 17S-resolvins has been shown to occur in 
human whole blood, isolated leukocytes, and glial cells while neuroprotectin is formed 
from DHA in corneal cells and maresin synthesized in monocytes.59,110,111 Also, cell-cell 
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interactions between endothelial cells and leukocytes produce resolvin from DHA.56 Such 
involvement of vascular cells confirms that they are at least in part able to produce the 
mediators necessary for resolution of their own injury. It would be of interest to identify 
whether vascular cells could individually produce SPMs from DHA as a means for local 
and efficient treatment of vascular inflammation. Furthermore, tracking how their 
biosynthesis is enzymatically mediated may serve as an initial investigation for potential 
pharmaceutical intervention. 	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Specific Aims 
SPMs act to resolve vascular inflammation and may contribute significantly to the 
prevention of atherosclerotic stenosis and restenosis following vascular procedures. 
Stimulating synthesis of these mediators directly in vascular cells may increase their local 
availability, and thus, their role in limiting such conditions. However, the ability of 
endothelial and vascular smooth muscle cells to produce SPMs from their PUFA 
precursors remains unknown.  
 The purpose of this study is to determine whether vascular cells can produce 
SPMs from DHA and, if they do, how inflammation and mechanical injury of the 
vasculature alter biosynthesis. Specifically, we aim to: 
1) Identify which SPMs are produced in human EC and VSMC as well as in ex vivo 
isolated blood vessels following treatment with DHA. 
2) Investigate dose and time dependent responses of RvD1 production in EC and 
VSMC after DHA treatment. 
3) Characterize changes in RvD1 biosynthesis due to inflammatory and injury 
related stimuli. 
4) Determine the mechanism of DHA and TNF alteration of RvD1 production by 
investigating patterns of LO expression and localization. 
By achieving these aims, we hope to ultimately introduce the foundation for new 
approaches to avoiding restenosis following vascular intervention.
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METHODS  	  
Reagents, Cells, and Treatment Protocol 
Primary cultures of human greater saphenous vein ECs and VSMCs were isolated 
from saphenous vein discarded at the time of bypass operation in a University of 
California–San Francisco Institutional Review Board-approved protocol as described 
previously.112 VSMC were maintained in Dulbecco's Modified Eagle's Medium (DMEM; 
low glucose; HyClone, Logan, UT) containing 10% FBS (Invitrogen Life Technologies, 
Grand Island, NY) penicillin/streptomycin/amphotericin B (Lonza 1760) and used 
between passages 2 and 5. EC (passage 2 to 5) were maintained in Media 199 with 
Earle's Balanced Salt Solution (Hyclone, Logan, UT) supplemented with 10% FBS, 
penicillin/streptomycin/amphotericin B (Lonza 1760), ECGS (BD Cat no. 356006) and 
heparin (17.5 U/ml). DHA (4Z, 7Z, 10Z, 13Z, 16Z, 19Z- docosahexaenoic acid) was 
obtained from Cayman Chemicals (Ann Arbor, MI). Cells were treated with DHA (50-
1000nM) and TNF-α (1ng/ml) at time points of 4, 8, and/or 24 hours. 
 
Sample Extraction and Mediator Lipidomics 
Solid-phase extraction columns were used for sample extraction for LC-MS/MS as 
described previously.113 500 pg of deuterium-labeled internal standards d8-5S-
hydroxyeicosatetraenoic acid (HETE), d4-leukotriene B4, (LTB4) d5-lipoxin A4 (LXA4) 
and d4-prostaglandin E2 (PGE2) were added before extraction to enable the quantification 
of sample recovery. Extracted samples were analyzed by a LC-UV-MS/MS system, 
QTrap 6500 (AB Sciex, Framingham, MA, USA) equipped with two Shimadzu LC-
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20AD pumps (Shimadzu Corp., Kyoto, Japan). An Agilent Eclipse Plus C18 column 
(100×4.6 mm×1.8 μm; Agilent Technologies, Santa Clara, CA, USA) was used with a 
gradient of methanol/water/acetic acid of 60:40:0.01 (v/v/v) to 100:0:0.01 at 0.4 ml/min 
flow rate. Identification was conducted using previously published criteria using a 
minimum of 6 diagnostic ions.113 Quantification was carried out based on the peak area of 
the multiple reaction monitoring transition and the linear calibration curve for each 
compound. 
 
RvD1 ELISA 
An enzyme-linked immunosorbent competition-based assay (ELISA) was used to 
detect RvD1 levels in the cell culture supernatant as described by the manufacturer 
(Cayman Chemical Company, Ann Arbor, MI, USA). This assay is based on the 
competition between free RvD1 in either the cell culture media or cellular extract and an 
RvD1 tracer linked to acetylcholinesterase. 
 
Western Blotting 
VSMC and EC were lysed in CellLytic M buffer (Sigma, Cat no. C2978) and, after 
three pulses of low watt sonication on ice, heated at 100°C in Laemlli buffer for 7 min. 
The lysate (25 μg) was then run on NuPAGE 10% Bis-Tris gel (Invitrogen) and 
transferred to a PVDF membrane that was probed with anti-5 lipoxygenase antibody 
(1:500; Novus Biologicals, Littleton, CO, USA), anti-15 lipoxygenase antibody (1:400; 
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Novus Biologicals) and anti-β-actin (1:4000; Sigma-Aldrich, St. Louis, MO, USA) using 
a QDot 625 Western blotting kit (Invitrogen). 
 
Immunofluorescence for 5-LO Localization 
All immunofluorescence staining was completed on 4-well chamber slides (EMS, 
Hatfield, PA). After treatment, cells were briefly rinsed in PBS and fixed with 4% 
paraformaldehyde for 20 min at 37°C, followed by permeabilization in ice-cold acetone 
(10 min at −20°C) and 1% Triton-X100 (20 min at room temperature). Cells were 
incubated at 4°C overnight with anti-5-lipoxygenase antibody followed by goat anti-
rabbit IgG-conjugated Alexa Fluor 488 (Life Technologies, Carlsbad, CA). Fluorescence 
imaging was completed with an Olympus BX51 microscope (Olympus America, Center 
Valley, PA, USA) with an EXFO X-cite 120 system (EXFO Photonic Solutions, 
Mississauga, ON, Canada), Olympus DP70 digital microscope camera, and DPController 
software (Olympus). Ten section zones (at ×20 view) were selected randomly on 4 
coordinate axes of every well. 5-lipoxygenase localization was quantified through 
comparison of relative mean cytoplasmic to nuclear intensity with IMAGEJ software. 
 
Rabbit Aorta Extraction and Endothelial Denudation 
All rabbit specimens were harvested from animals freshly euthanized as part of the 
IACUC approved UCSF tissue sharing program. Female New Zealand white rabbits 
(NZWRs; Western Oregon Rabbit Company, Philomath, OR, USA) weighing 3 to 5 kg 
and maintained on a normal chow diet (LabDiet Rabbit Diet High Fiber; Purina, St. 
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Louis, MO, USA) were used in all experiments. Aortas were harvested from distal to the 
left subclavian artery down to the aortic bifurcation with care to avoid excessive stretch 
or other damage to the vessel. The aorta was then opened en face and divided into 1cm2 
sections. Endothelial cells were denuded via cotton swab for the (-) endothelial cell 
groups.  
Samples were immersed in either DHA free or 1000nM DHA containing DMEM and 
incubated at 37°C for 48hrs. Media was spun in 30kD centrifugal tubes (Merck Millipore 
Ltd; Darmstadt, Germany) and assessed for RvD1 production by ELISA. Tissues was 
collected and immediately snap-frozen for metabololipidomic profiling by LC-MS/MS or 
ELISA, and cryosections were prepared for immunohistochemistry. 
Immunostaining was performed to evaluate the quality of endothelial denudation. 
Monoclonal antibody against CD31 (1:50, JC70A; Dako Denmark A/S, Glostrup, 
Denmark) was used for primary antibody, a biotinylated goat-anti mouse for secondary 
(1:200; Invitrogen) and sections were counterstained with streptavidin-conjugated 
fluorescin (1:200; Vector, Burlingame, CA, USA). 
 
Statistical Analysis 
Data are shown as means ± SE. Direct comparisons were made using unpaired or 
paired Student's t test, and multiple group comparisons were made using 1-way or 2-way 
ANOVA followed by Bonferroni's post hoc tests where appropriate. In all cases, a level 
of P < 0.05 was considered significant. 
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RESULTS 	  
Biosynthesis of Pro-resolving Lipid Mediators from DHA in Vascular Cells 
 The generation and accumulation of pro-resolving mediators within the vessel 
wall has been characterized previously. However, the ability of vascular cells to produce 
SPMs in the absence of leukocytes has not been demonstrated. LC-MS/MS was 
preformed to identify de novo SPM generation in vitro in EC and VSMC cultures 
following 24 h treatments of 1000nM DHA (Figure 3). In the collected media, we 
identified the presence of the following DHA derived precursors and downstream 
bioactive mediators: 17-HDHA (4500 ± 250 pg/ml in EC; 2300 ± 130 pg/ml in VSMC), 
14-HDHA (345 ± 23 pg/ml in EC; 110 ± 25 pg/ml in VSMC), MaR1 (235 ± 28 pg/ml in 
EC; 245 ± 22 pg/ml in VSMC) and RvD5 (1.6 pg/ml in EC; 3.45 ± 0.35 pg/ml in 
VSMC). Low levels (0.5 pg/ml) of RvD2 were also detected in both cells. Though not 
detected in LC-MS/MS analysis, high levels of RvD1 (30 pg/ml) were measured in both 
EC and VSMC through ELISA. 
It should be noted that all experiments were performed in 10% fetal bovine serum, 
likely containing trace levels of PUFA precursors. Consequently, marginal levels (<0.5 
pg/ml) of various AA and EPA derived mediators were observed in all samples. DHA 
supplementation significantly induced SPM biosynthesis from baseline levels in both EC 
and VSMC. 
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Time and Does Dependent Affects on DHA Mediated RvD1 Generation 
We next sought to identify a time profile of SPM production to find time points of 
interest for investigating modulation of SPM biosynthesis. RvD1 was chosen for detailed 
analysis because of the availability of an ELISA for its detection. Because all 
experiments were performed in 10% serum, there were low levels of RvD1 released in 
untreated cells. In EC, increasing DHA doses displayed a similar progression of RvD1 
Lipid Mediator Metabololipidomics 
Qtrap 6500 analysis 
0.5ng d4-PGE2 
0.5ng d8-5-HETE 
0.5ng d4-LTB4 
0.5ng d5-LXA4 
0.5ng d5-RvD2  
Dr. Jason HELLMANN 03-06-15 
Dr. Matthew SPITE 
Brigham and Women’s Hospital 
Harvard Medical School 
17-HDHA
Ct
rl
+D
HA Ct
rl
+D
HA
0
2000
4000
6000
EC SMC
pg
/m
L
***
***
14-HDHA
Ct
rl
+D
HA Ct
rl
+D
HA
0
100
200
300
400
500
EC SMC
pg
/m
L
***
***
MaR1
Ct
rl
+D
HA Ct
rl
+D
HA
0
100
200
300
pg
/m
L
EC SMC
*** ***
RvD5
Ct
rl
+D
HA Ct
rl
+D
HA
0
1
2
3
4
5
EC SMC
pg
/m
L
*
Figure 3. Local biosynthesis of pro-resolving lipid mediators in vascular cells. 
Cells were treated with DHA (1000nM) for 24 h. Representative profiles from LC-
MS/MS display the generation of pro-resolving lipid mediators in EC and VSMC.  
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synthesis, with a rapid initial rate of generation that tapered over the course of 24 hours 
(Figure 4A). In untreated cells, total RvD1 production from baseline was 0.39 ± 0.05 pg 
in the first 4 hours, 0.52 ± 0.01 pg in the first 8 hours (33% increase from previous 4 
hours), and 0.84 ± 0.05 pg in 24 hours (38% increase over previous 16 hours). Increasing 
substrate availability enhanced the initial rate of RvD1 generation, with 4 h levels at 0.47 
± 0.05 pg for 50nM DHA, 0.83 ± 0.15 pg for 100nM DHA, 1.72  ± 0.08 pg for 300nM 
DHA, 2.43 ± 0.25 pg with 500nM DHA (p<.01 compared to 4 h ctrl), for 5.19 ± .53 pg 
with 1000nM DHA (p<.001 compared to 4 h ctrl). Similarly, the rate of biosynthesis 
from 4 to 8 hours rose slightly following DHA treatment, with increases between 40% 
and 80% measured for each dose during the time period. RvD1 levels changed minimally 
thereafter for all doses, with 24 h totals of 1.02 ± 0.03 pg for 50nM DHA, 1.3 ± 0.34 pg 
for 100nM DHA, 2.89 ± 0.21 pg for 300nM DHA (p<.01 compared to 24 h ctrl), 4.72 ± 
0.27 pg for 500nM DHA (p<.001 compared to 24 h ctrl), and 10.1 ± 1.05 pg for 1000nM 
DHA (p<.001 compared to 24 h ctrl). 
Meanwhile, VSMC displayed an analogous time and dose dependent pattern of 
RvD1 biosynthesis, with all treatment groups producing the majority of total product 
within 4 hours of treatment (Figure 4B). RvD1 levels at 4 hours were 0.36 ± 0.07 pg for 
control, 0.35 ± 0.04 pg for 50nM DHA, 1.55 ± 0.48 pg for 100nM DHA, 2.72 ± 0.3 pg 
300nM (p<.001 compared to 4 h ctrl), 4.4 ± 0.28 pg for 500nM (p<.001 compared to 4 h 
ctrl), and 6.82 ± 0.81 pg for 1000nM (p<.001 compared to 4 h ctrl). The rate of 
production slowed even more considerably than in EC thereafter, such that the total 
generation of RvD1 plateaued at 24 h at 0.64 ± 0.21 pg for control, 1.29 ± 0.06 pg for 50 
	  25 
nM, 1.65 ± 0.41 for 100nM DHA, 3.03 ± 0.16 pg for 300nM DHA (p<.001 compared to 
24 h ctlr), 4.94 ± 0.43 pg for 500nM (p<.001 compared to 24 h ctlr), and 7.43 ± 0.22 pg 
for 1000nM DHA (p<.001 compared to 24 h ctlr). It is of note that maximum RvD1 
production (24 h following 1000nM DHA treatment) was 26% higher in EC than VSMC. 
 
 
Enzymatic Regulation of RvD1 Pathway 
A 1000nM dosage of DHA was selected for all subsequent experiments, as this 
dose gave maximal RvD1 production and is physiologically closest to standard serum 
concentration for DHA. 
Figure 4. Time and dose dependent effects of DHA mediated RvD1 synthesis. 
Endothelial (A) and smooth muscle cells (B) were treated with DHA (50-1000nM) 
for 4, 8, and 24 h. Media was collected for ELISA. Results are shown as net RvD1 
produced. n=3, *:P < 0.05 compared to untreated control at respective time points; 
†: p≤0.05 compared to 4 h treatment; 2-way ANOVA with Bonferroni's post hoc 
test. 
A B 
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With the expectation that 5-LO and 15-LO drive the transformation of DHA to 
RvD1, we investigated their expression in ECs and VSMCs. Western blot analysis 
confirmed the presence of 5-LO in EC (Figure 5A) and VSMC (Figure 5C). In EC, 5-
LO expression did not change at either 4 or 8 h following 1000nM DHA treatment but 
increased by 94% (p=.045) at 24 h. In comparison, expression in VSMC remained 
constant throughout the treatment. Meanwhile, 15-LO expression was also observed in 
EC (Figure 5B) and VSMC (Figure 5D). Representative bands were noticeably weaker 
than for 5-LO. 15-LO expression did not vary at any point post-treatment in either cell 
type. 
 
 
Figure 5. Expression of 5-LO and 15-LO in vascular cells.  
A-D) Time-dependent expression of 5-LO and 15-LO in DHA (1000nM) treated EC 
(A,B) and VSMC (C,D) assessed by western blot analysis. n=3, *P < 0.05 compared 
to control; unpaired t test. 
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The affects of DHA treatment (1000nM) on 5-LO cellular localization were also 
examined (Figure 6). Previous studies have associated increased cytoplasmic presence of 
5-LO with SPM biosynthesis. Experiments were with 5 and 24 hours treatments to 
represent the aforementioned phases of rapid and stalled RvD1 biosynthesis. In both EC 
and VSMC, DHA caused a significant shift of 5-LO localization from the nucleus to 
cytoplasm at 5 h (27%, p=.014; 38%, p<.001, respectively). Translocation was not 
observed at 24 h in either cell, with 5-LO remaining mostly in the nucleus. 
 
 
RvD1 Production is Reduced Following Endothelial Denudation ex vivo  
The relative contribution for RvD1 production of EC versus VSMC in an ex vivo 
vessel model was investigated. Following extraction from the rabbit, isolated aorta was 
Figure 6. Effect of DHA on sub-cellular distribution of 5-LO.  
A-F) Representative immunofluorescence images of 5-LO in EC (A-C) and VSMC 
(D-F) with IgG control (A, D), 5-LO untreated control (B, E) and 5-LO DHA treated 
cells (1000nM for 5h; C,F) .(G, H) Quantitative analysis of 5-LO translocation (ratio 
of cytoplasmic to nuclear fluorescence) in EC (G) and VSMC (H). n≥3 where n= each 
well of a 4-well chamber slide. *P < 0.05 compared to 5-LO control; unpaired t test.  
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promptly denuded. Successful removal of endothelium was confirmed by 
immunostaining for CD31 (Figure 7B-C). After 48 hour incubation in 1000nM DHA, 
media was assessed for RvD1 production. Both undenuded (90% increase, p=.02) and 
denuded (112% increase, p<.001) aorta saw substantial increases in RvD1 production 
with DHA treatment (Figure 7D). Furthermore, endothelial denudation caused a 
significant decrease in synthesis relative to the intact vessel (28% decrease, p=.026). 
 
 
 
A B 
C 
Figure 7. DHA induced RvD1 production in intact and endothelium-denuded 
rabbit aorta. 
A-B) Immunofluorescence images of sections of rabbit aorta stained with endothelial 
marker CD31. (A) IgG control (B) intact aorta (+EC) and (C) denuded aorta. (D) 
Rabbit aorta segments (1cm2 area) were incubated for 48hrs in media with and without 
1000nM DHA and RvD1 production was measured with ELISA. Results are shown as 
net RvD1 produced per mg vessel tissue. n=3, *P < 0.05 compared to nondenuded and 
untreated vessel (+EC/-DHA), unpaired t test.  
IgG	  
Ctrl 
CD31,	  +EC 
CD31,	  -­‐EC D 
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Inflammatory Cytokines Enhance DHA Derived RvD1 Biosynthesis in EC 
We monitored the impact of TNF-α on RvD1 production in endothelial cells to assess 
the impact of inflammatory cytokines on SPM pathways. A TNF-α dose of 1 ng/ml was 
selected for optimal stimulation of EC. In the absence of substrate, TNF-α did not 
increase RvD1 production above baseline levels. Meanwhile, DHA treatment resulted in 
a modest rate of increase in RvD1 following the initial 4 hours (26% increase from 4 to 8 
h and 26% from 8 to 24 h). Simultaneous treatment of DHA with TNF-α produced a 
similar initial trend in RvD1 synthesis (9.47 ± 2.66 pg in first 4 hours with a 15% 
increase in the next 4 h). Though slightly higher than RvD1 generated by DHA alone, 
increases were not significant. However, RvD1 production did not taper in the next 16 
hours, increasing by 63% to 18.62 ± 1.26 pg at 24 h (p<.001 compared to DHA at 24 h) 
(Figure 8A).  
To explain these effects, we explored TNF-α influence on 5-LO expression and sub-
cellular localization. Expression was significantly induced following 24 h treatment 
(113%, p=.0069) (Figure 8B). Similarly, TNF-α (5 h treatment) caused a significant shift 
of 5-LO localization from the nucleus to cytoplasm (81%, p<.001; Figure 8C-F).  	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Figure 6. TNF augments RvD1 biosynthesis in EC through 5-LO expression and 
cytoplasmic translocation. A) Time-dependent response of TNF on DHA induced 
RvD1 production. EC were treated with DHA (1000nM) and TNF (1ng/ml) for 4, 8, 
and 24 h. Media was collected for ELISA. Results are shown as net RvD1 produced in 
approx 175ul per well of a 24-well plate. n=3, *:P < 0.05 compared to untreated 
control at respective time points; †: p≤0.05 compared to 4 h treatment; ‡:P<0.05 
compared to 8 h treatment; 2-way ANOVA with Bonferroni's post hoc test. #:P < 0.05 
compared to DHA; unpaired t test.  B) TNF up-regulates 5-LO expression in EC at 24 
h. n=3, *:P < 0.05 compared to control; unpaired t test. C-D) Representative 
immunofluorescence images showing 5-LO cytoplasmic translocation in EC with 
TNF-α (1ng/ml) at 5 h (D), compared to untreated control (C). E) Quantitative 
analysis of 5-LO translocation in C-D (ratio of cytoplasmic to nuclear fluorescence) in 
EC. n≥3 where n= each well of a 4-well chamber slide. *:P < 0.05 compared to 
control; paired t test.  
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DISCUSSION 	  
Acute vascular injury resulting from vascular interventions performed for occlusive 
cardiovascular disease (e.g. angioplasty, stents, bypass grafts, etc.) often results in the 
development of neointimal hyperplasia and eventual restenosis.45 Recent evidence 
indicates that restenosis can be viewed as a resolution deficit within the vessel wall.9 
Thus, the availability of pro-resolving lipid mediators in the vasculature is critical for the 
resolution of acute inflammation after intervention, halting the underlying cause of 
restenotic injury. While it is clear that SPMs are present and play an active role in 
resolution after vascular intervention, the specific ability of endothelial and vascular 
smooth muscle cells to independently synthesize these mediators was previously 
unknown. The findings reported in this study indicate that, in the absence of leukocytes 
and other cells known to produce pro-resolving mediators, cells and tissue of vascular 
origin can produce SPMs from DHA. 
Our LC-MS/MS results revealed 17-HDHA, 14-HDHA, and MaR1 to be the major 
products of DHA derived SPM biosynthesis, accompanied by minor generation of RvD5 
and RvD2. On initial consideration, these findings suggest that SPM pathways in vascular 
cells are skewed towards the production of MaR1, as it is the only biologically active pro-
resolving mediator measured at significant levels. However, the predominance of the 
resolvin and protectin intermediate product, 17-HDHA, over the maresin intermediate, 
14-HDHA, implies that resolvin production pathways are also active. Furthermore, 
although mass spectrometry did not reveal RvD1 production, high amounts were detected 
with ELISA. The absence of detected 17-HDHA downstream products in LC-MS/MS 
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could be attributed to issues with column extraction, specificity of 5-LO for 14-HDHA 
over 17-HDHA, or relatively high rates of resolvin degradation. Though incomplete, 
these findings ultimately suggest that in the presence of precursor PUFAs, endogenous 
pathways of pro-resolving mediator production are biochemically active in vascular cells. 
Furthermore, we found that RvD1 biosynthesis is a dynamic process, subject to time 
and DHA dose dependent rises and mediated by the action of 5-LO and 15-LO. Previous 
studies had established that these enzymes are expressed in both EC and VSMC.95–98 We 
confirmed this and found that DHA upregulates 5-LO protein expression over time in EC. 
Although the explanation for this observed increase remains unclear, various possibilities 
exist that are centered around transcriptional regulation. There is evidence that DHA 
restricts global DNA methylation and may induce 5-LO expression through 
demethylation of its promoter sequence in DNA.114,115 Meanwhile, DHA may increase 
activity of NF-κB, a transcription factor for 5-LO, inducing the formation of the 
transcriptional preinitiation complex.116,117 Further investigation of mRNA profiles under 
experimentally controlled transcriptional regulation is necessary for clarification of the 
exact mechanism and to explain why no such effects are observed in VSMC.  
Despite differences in measured 5-LO expression between EC and VSMC at 24 
hours, neither cell type underwent changes in 5-LO nor 15-LO protein levels within the 
initial 4 hours of treatment, the time frame for the majority of RvD1 formation. This 
initial rise in RvD1 production may be in part explained by a DHA mediated nuclear to 
cytoplasmic shift in 5-LO localization in both EC and VSMC, as the cytoplasm is the site 
of RvD1 synthesis. Such an effect of substrates on 5-LO subcellular position is not 
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unprecedented, as studies have shown AA induced phosphorylation of Ser-271 in 5-LO 
to promote nuclear shift of the enzyme.105 It is possible that DHA plays a similar role in 
mediating this process. However, DHA derived RvD1 may also regulate cytoplasmic 
shift as part of a feed-forward mechanism through phosphorylation of 5-LO Ser-523.104 
Whether DHA influences 5-LO localization directly, indirectly through RvD1 synthesis, 
or through a combination of both mechanisms is uncertain, and further studies are 
necessary to clarify the exact pathway. 
Assessment of RvD1 production in isolated rabbit aorta revealed that vessels devoid 
of endothelial cells generated significantly lower levels of RvD1 than intact aorta, 
suggesting a critical role for EC in SPM production within the vessel. The normal arterial 
wall comprises of a single layer of endothelium sitting on top of a thick tunica media that 
is composed mainly of vascular smooth muscle cells. Thus, it is noteworthy that 
relatively such few EC produce over a quarter of all RvD1 synthesized in a blood vessel. 
Similarly, we observed that endothelial cells produced more RvD1 than VSMC in cell 
culture. These results suggest that the lack of EC may attenuate resolution pathways in 
the vessel, potentially contributing to the inability of deendothelialized vessels to prevent 
the progression of neointimal hyperplasia. 
One of the prominent findings of this study was that TNF increased RvD1 production 
in EC, suggesting that endothelial cells may actively participate in a self-resolving acute 
inflammatory response. The fact that this surge in RvD1 generation does not become 
significant until after 24 h treatment with TNF is particularly important and indicates the 
occurrence of lipid mediator class switching in EC. In PMNs and monocytes, acute 
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inflammatory insult has been shown to produce a temporal regulation of lipid mediator 
generation from pro-inflammatory to pro-resolving over time.118,119 Our investigation 
found that upregulation of 5-LO expression at 24 h coincided with its nuclear to 
cytoplasmic shift in the cell, indicating that increases of the enzyme correspond with 
RvD1 production over that of leukotrienes. These findings suggest that vascular cells 
endogenously respond to inflammatory insult by promoting synthesis of pro-resolving 
mediators. 
In summary, human vascular cells and rabbit vascular tissue can biosynthesize SPMs 
de novo from the precursor DHA and may contribute to self-resolution of acute vascular 
inflammation associated with neointimal hyperplasia. We hope that these findings initiate 
investigation of novel therapeutic options aimed at promoting endogenous biosynthesis of 
SPMs in the vasculature to combat the progression of vascular injury. 	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Research Experience 
Stanford Stroke Center, Palo Alto, CA 05/11-08/12 
Research Volunteer 
 
• Participated in clinical research focusing on the diagnostic capabilities of medical 
imaging for cause of stroke.  
• Analyzed MRI and CT images for investigation of: 
o coma patient prognostication 
o ischemia surrounding intracerebral hemorrhage 
 
Volunteer Experience 
bWell Center, Boston, MA 01/14-05/14 
Medical Volunteer in Pediatrics 
• Provided health resources for patients and their families. 
• Led “Jump Rope Clinic” to advocate a healthy lifestyle for patients.  
• Acted as patient liaison: 
o Directed patients to appointments 
o Entertained kids in waiting room 
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Armenian Volunteer Corps, Yerevan, Armenia 05/13-07/13 
Medical Volunteer in Pediatric Orthopedic Department 
• Assisted in clinical practice. 
o Assisted in applying casts on patients. 
o Prepared patient rooms for clinical use. 
• Observed surgical procedures ranging from polydactyly adjustment to tendon 
lengthening. 
• Applied suturing at termination of operations. 
John Muir Hospital, Walnut Creek, CA 06/10-06/12 
ER Volunteer 
• Aided in maintaining patient records. 
• Assisted in preparation of rooms for clinical use. 
• Acted as patient liaison. 
• Observed care of trauma patients. 
 Leadership Experience 
St. Andrew’s Armenian Apostolic Church, Cupertino, CA 10/09-Present 
Deacon Service 
• Advised members of congregation on spiritual issues. 
• Helped plan and organize church events. 
• Participated in Sunday Service. 
UC Berkeley Habitat for Humanity, Berkeley, CA 02/10-05/13 
Workday Coordinator 
• Planned, organized, and led weekly volunteer outings. 
• Met with various non-profit organizations throughout the Bay Area to discuss our 
chapter’s potential involvement in their projects. 
• Helped organized fundraisers to fund volunteer excursions. 
Homenetmen Scouting, Santa Clara, CA 09/09-06/11 
Youth Leader and Mentor 
• Involved in program development and institution of troop 300. 
• Met with youth leaders to discuss and advise on current and future directions of 
chapter. 
• Gave educational lectures and led hikes. 
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 Presentations 
International Stroke Conference, New Orleans, LA 02/12 
Blood Pressure Thresholds to Predict the Cause of Intracerebral Hemorrhage 
 
	  
